|
| Friday, April 17, 2015 |
|
|
Cytokinetics to Announce First Quarter Results on April 30, 2015 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 30, 2015 at 4:00 PM Eastern Time. more info >> |
|
| Tuesday, April 14, 2015 |
|
|
Cytokinetics to Host R&D Day on Tuesday, May 12, 2015 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to host its Research and Development Day on Tuesday, May 12, 2015. more info >> |
|
| Thursday, April 9, 2015 |
|
|
Cytokinetics to Present at the 14th Annual Needham Healthcare Conference |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 11:20 AM at the Westin New York Grand Central in New York, NY. more info >> |
|
| Thursday, March 26, 2015 |
|
|
Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of a manuscript relating to its fast skeletal muscle troponin activator tirasemtiv in the journal Neurotherapeutics. more info >> |
|
| Friday, March 13, 2015 |
|
|
Cytokinetics Announces Completion of Enrollment in COSMIC-HF |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) has completed enrollment of the approximately 450 patients planned in the expansion phase of the clinical trial. more info >> |
|
| Friday, February 27, 2015 |
|
|
Cytokinetics Announces Publication of Preclinical Data Relating to CK-2127107 and Exercise Tolerance in Rodent Model of Heart Failure |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of a manuscript relating to its fast skeletal muscle troponin activator CK-2127107 in The Journal of Pharmacology and Experimental Therapeutics. more info >> |
|
| Wednesday, February 25, 2015 |
|
|
Cytokinetics to Present at Healthcare Conferences in March |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences. more info >> |
|
| Friday, February 13, 2015 |
|
|
Cytokinetics, Incorporated Reports Fourth Quarter 2014 Financial Results |
| Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the fourth quarter of 2014 were $21.8 million, compared to $24.3 million during the same period in 2013. more info >> |
|
| Tuesday, December 23, 2014 |
|
|
Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications |
| Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas") announced today an amendment to their collaboration agreement focused on the research, development and commercialization of skeletal muscle activators. more info >> |
|
| Saturday, December 6, 2014 |
|
|
Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle Function at International Symposium on ALS/MND |
| Cytokinetics (Nasdaq: CYTK) announced today that an oral presentation and four poster presentations relating to tirasemtiv were presented at the 25th International Symposium on ALS/MND held at the Square Brussels Meeting Centre in Brussels, Belgium. more info >> |
|
|
|
|
